drugset

drugset / Trial / NCT03583489

Study of APD421 With and Without Ondansetron

NCT03583489 ↗

Phase 1 Completed 30 enrolled Acacia Pharma Ltd

RandomizedCrossoverQuadruple-blindOther

Summary

Collection of pharmacokinetic and electrocardiograph data from healthy volunteers given APD421 +/- ondansetron

Timeline

Start: 2018-07-17
Primary completion: 2018-08-13
Completion: 2018-08-13

Publications

Fox GM, Albayaty M, Walker JL, Xue H, Darpo B. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2021 Jan;132(1):150-159. doi: 10.1213/ANE.0000000000004538.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amisulpride	Small molecule	10 mg	Intravenous
Subject	Ondansetron	Other / unclassified	4 mg	Intravenous

Indications

No indication recorded.